Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Inhibition of steroid sulfatase (STS) activity in skin is a potential new treatment strategy for a number of skin disorders, including hirsutism, androgen-dependent alopecia, acne and psoriasis. In skin and its appendages, STS regulates the hydrolysis of dehydicep androsterone sulfate to dehydroepiandrosterone, a weak androgen, which can be converted to the biologically active androgens testosterone and 5α-dihydrotestosterone by other steroidogenic enzymes also present in skin. A number of potent, irreversible STS inhibitors have been developed based around a core arylsulfamate ester motif, the active pharmacephore required for potent STS inhibition. Such inhibitors include AHBS and STX-64. Topical application of AHBS to the skin of mice or pigs resulted in almost complete inhibition of skin STS activity. Furthermore, when applied to the skin of Göttingen minipigs daily for 2 weeks, by day 10 AHBS had inhibited sebum production, a desired requisite for an anti-acne drug. When applied topically to the skin of nude mice at 1.0 and 10.0 mg/kg STX-64 inhibited skin STS activity by > 90%, but it also inhibited liver STS activity. While preclinical studies have confirmed the ability of topically applied STS inhibitors to inhibit skin STS activity, further studies using preclinical models of skin disorders and clinical trials are needed to test their efficacy in treating skin disorders. Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.

Original publication

DOI

10.1358/dof.2008.033.07.1212711

Type

Journal article

Journal

Drugs of the Future

Publication Date

01/07/2008

Volume

33

Pages

597 - 606